Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

Paliperidone has a number of advantages over SRIs (the commonly prescribed medication), including fewer drug interactions and better tolerability. This study is designed to determine whether adding paliperidone to an existing medication (an SRI) is more effective in reducing OCD symptoms compared to taking a placebo and an existing medication (SRI). Patients accepted into this study will receive physicals, psychiatric exams, labs, ECG, and study medication all at no cost to the patient. There will be 8 visits over 10 weeks. For each completed study visit, $15 will be reimbursed to the patient for travel and meal expenses.

Organization: 
University of South Florida
Principal Investigator: 
Eric A. Storch, PhD
Eligibility Criteria: 
  • Diagnosis of OCD or OCD w/ other comorbidities provided OCD is chief complaint
  • Age 18-70 and in good health
  • OCD symptoms of at least one-year duration
  • 2 adequate (12 weeks or more) SRI monotherapy trials
  • Y-BOCS e 19
Exclusion Criteria: 
  • Primary diagnosis of depression, schizophrenia, active bipolar disorder or other psychotic disorders
  • Non-responsive to atypical antipsychotic augmentation or CBT
  • Substance or alcohol abuse past 6 months
  • History of seizure disorder, encephalitis, or significant head injuries or a significant medical condition such as heart, liver, or renal disease
  • Nursing mothers or women of childbearing potential who don’t use adequate contraception
Contact: 
Eric Storch, PhD, (352) 392-3613 or estorch@health.usf.edu; Nikki Ricciuti, LMHC, (352) 392-3613 or nikkir@ufl.edu
Location: 
St. Petersburg, FL
State: 
Florida
Study End Date: 
Tue, 2010-08-31

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Privacy Policy 
© ADAA, 2010-2014

<